Promising Three-Drug cocktail targets tough leukemia

NCT ID NCT07486726

First seen Apr 21, 2026 · Last updated May 14, 2026 · Updated 4 times

Summary

This study tests a new combination of three drugs (aclarubicin, azacitidine, and venetoclax) for people with acute myeloid leukemia (AML), including those newly diagnosed or whose cancer has returned. The goal is to find the safest dose and see if the combo helps control the disease. About 112 adults aged 18 and older will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA (AML) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai

    Shanghai, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Shanghai Jing'an District Beizhan Hospital

    Shanghai, China

    Contact Phone: •••-•••-••••

  • Shanghai Traditional Chinese Medicine Hospital

    Shanghai, China

    Contact Email: •••••@•••••

  • Tongren Hospital, Shanghai Jiao Tong University School of Medicine

    Shanghai, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.